Skip to main content
. 2022 Mar 15;28:219–230. doi: 10.1016/j.omtn.2022.03.008

Figure 1.

Figure 1

Identification of SIAH1 as a biomarker in PCa progression

SIAH1 expression was analyzed in GSE6919 (A), GSE3325 (B), and GSE54460 datasets (C). (D) SIAH1 expression was analyzed in localized PCa, metastatic PCa tumor tissue, and adjacent normal tissues in GSE6919 datasets. (E) qPCR analysis of SIAH1 expression in PCa tissues and adjacent normal tissues. The 2−ΔΔCt method was used to quantify relative SIAH1 level, and the results were expressed as Log2 (2–ΔΔCt). (F) qPCR analysis of SIAH1 expression in BPH tissues, PCa tissues, and CRPC tissues. (G) Western blot analysis of SIAH1 expression in BPH tissues, PCa tissues, and CRPC tissues. (H) qPCR analysis of SIAH1 expression in PZ-HPV-7, 22Rv1, LNCaP, VCaP, PC3, and DU145 cells. (I) qPCR analysis of SIAH1 expression in PZ-HPV-7, 22Rv1, LNCaP, VCaP, PC3, and DU145 cells under androgen replete conditions or androgen deprivation. (J) Cell growth was detected in 22Rv1 cells with or without SIAH1 overexpression under androgen replete conditions or androgen deprivation using CCK-8 assay. (K) 22Rv1 cells invasion was assessed using transwell invasion assay after SIAH1 overexpression under androgen deprivation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.